Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 9—September 2020
Synopsis

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States

Roosecelis B. Martines1Comments to Author , Jana M. Ritter1, Eduard Matkovic, Joy Gary, Brigid C. Bollweg, Hannah Bullock, Cynthia S. Goldsmith, Luciana Silva-Flannery, Josilene N. Seixas, Sarah Reagan-Steiner, Timothy Uyeki, Amy Denison, Julu Bhatnagar, Wun-Ju Shieh, Sherif R. Zaki, and COVID-19 Pathology Working Group
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.B. Martines, J.M. Ritter, E. Matkovic, J. Gary, B.C. Bollweg, C.S. Goldsmith, L. Silva-Flannery, J.N. Seixas, S. Reagan-Steiner, T. Uyeki, A. Denison, J. Bhatnagar, W.-J. Shieh, S.R. Zaki); Synergy America Inc., Atlanta (H. Bullock).

Main Article

Figure 2

Histopathologic findings associated with underlying conditions in fatal coronavirus disease. A) Patient no. 2: lung, hemosiderin-laden macrophages (brown pigment, bottom left), and anthracosis (black pigment, top right) in a patient with congestive heart failure (original magnification ×20). B) Patient no. 3: lung, emphysema in a patient with chronic obstructive pulmonary disease (original magnification ×5). C) Patient no. 7: lung, pulmonary microthrombosis (arrow) (original magnification ×20).

Figure 2. Histopathologic findings associated with underlying conditions in fatal coronavirus disease. A) Patient no. 2: lung, hemosiderin-laden macrophages (brown pigment, bottom left), and anthracosis (black pigment, top right) in a patient with congestive heart failure (original magnification ×20). B) Patient no. 3: lung, emphysema in a patient with chronic obstructive pulmonary disease (original magnification ×5). C) Patient no. 7: lung, pulmonary microthrombosis (arrow) (original magnification ×20). D) Patient no. 2: kidney, extensive glomerulosclerosis in a patient with renal disease (original magnification ×10). E) Patient no. 3: liver, steatosis in a patient with morbid obesity (original magnification ×20). F) Patient no. 2: heart, myocardial fibrosis and mild cardiomyocyte hypertrophy in a patient with cardiomegaly (original magnification ×5).

Main Article

1These authors contributed equally to this article.

2Members of the COVID-19 Pathology Working Group: Rhonda Cole, Amanda Lewis, Pamela Fair, Lindsey Estetter.

Page created: May 21, 2020
Page updated: August 18, 2020
Page reviewed: August 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external